HCPCS Code Detail Logo

HCPCS Codes Similar to M1343

HCPCS Codes Similar to “M1343” Code.
Patients who are at pam level 4 at baseline or patients who are flagged with extreme straight line response sets on the pam or with excessive missing responses

G2077
Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical and psychiatric treatment needs and goals; assessment may be informed by administration of a standardized, evidence-based social determinants of health risk assessment to identify unmet health-related social needs, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code
Code added date: 20200101
Code effective date: 20250101
G0543
Group caregiver training in direct care strategies and techniques to support care for patients with an ongoing condition or illness and to reduce complications (including, but not limited to, techniques to prevent decubitus ulcer formation, wound care, and infection control) (without the patient present), face-to-face with multiple sets of caregivers
Code added date: 20250101
Code effective date: 20250101
M1212
Glycemic status assessment (hba1c or gmi) level is missing, or was not performed during the measurement period
Code added date: 20240101
Code effective date: 20250101
M1344
Patients who did not have a baseline pam score and/or a second score within 4 to 12 months of baseline pam score
Code added date: 20240101
Code effective date: 20250101
M1345
Patients who had a baseline pam score and a second score within 4 to 12 month of baseline pam score
Code added date: 20240101
Code effective date: 20250101
M1385
Documentation of patient reasons for patients who were not seen for the second pam survey (e.g., less than four months between baseline pam assessment and follow-up
Code added date: 20250101
Code effective date: 20250101
M1346
Patients who did not have a net increase in pam score of at least 6 points within a 4 to 12 month period
Code added date: 20240101
Code effective date: 20250101
M1347
Patients who achieved a net increase in pam score of at least 3 points in a 4 to 12 month period (passing)
Code added date: 20240101
Code effective date: 20250101
M1348
Patients who achieved a net increase in pam score of at least 6-points in a 4 to 12 month period (excellent)
Code added date: 20240101
Code effective date: 20250101
M1349
Patients who did not have a net increase in pam score of at least 3 points within a 4 to 12 month period
Code added date: 20240101
Code effective date: 20250101
M1412
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
Code added date: 20250101
Code effective date: 20250101
M1413
Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
Code added date: 20250101
Code effective date: 20250101
M1415
Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
Code added date: 20250101
Code effective date: 20250101
GS
Dosage of erythropoietin stimulating agent has been reduced and maintained in response to hematocrit or hemoglobin level
Code added date: 20060101
Code effective date: 20130101